新型三价重组MVA载体马脑炎病毒疫苗的安全性与免疫原性:一项1期临床试验
该1期临床试验将45名健康成人纳入3个剂量组(1×10E7 Inf.U、1×10E8 Inf.U和2×10E8 Inf.U),间隔4周接种2剂MVA-BN-WEV疫苗并随访6个月。结果显示疫苗在所有剂量下安全性可接受,局部征集性不良事件发生率随剂量增加而升高,最高剂量组在第2剂后2周对WEEV和VEEV的血清转化率均为100%,对EEEV为92.9%,且6个月内观察到持久性。结论认为该疫苗耐受性良好、可诱导免疫反应,适合进一步开发。
要点
- MVA-BN-WEV疫苗在所有受试剂量下安全性可接受,未出现导致死亡或退出试验的不良事件。
- 最高剂量组第2剂后2周对WEEV和VEEV血清转化率均为100%,对EEEV为92.9%。
- 疫苗诱导的体液免疫应答随剂量增加而增强,并观察到6个月的持久性。
核心结论
- MVA-BN-WEV疫苗耐受性良好,可诱导免疫反应,适合进一步开发。
研究设计与样本
- 首次人体1期临床试验,纳入45名健康成人参与者,分为3个剂量组(1×10E7 Inf.U、1×10E8 Inf.U和2×10E8 Inf.U),间隔4周接种2剂,随后监测6个月。
主要发现
- MVA-BN-WEV在所有给药剂量下安全性特征可接受,局部征集性不良事件发生率随剂量增加而升高,剂量组间无其他有临床意义的差异。
- 最低剂量组报告1例严重不良事件(2级胸腔积液),评估为可能相关。
- 最常见的局部征集性不良事件为注射部位疼痛,全身征集性不良事件为头痛、疲乏和肌痛。
- WEEV、EEEV和VEEV特异性中和抗体应答在第2剂接种后2周达峰,应答幅度随剂量递增而增加。
- 最高剂量组在第2剂后2周对WEEV和VEEV的血清转化率均为100%,对EEEV为92.9%,并观察到6个月的持久性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Three encephalitic alphaviruses-western, eastern, and Venezuelan equine encephalitis virus (WEEV, EEEV and VEEV)-can cause severe disease and have the potential to be used as biological weapons. There are no approved vaccines for human use. A novel multivalent MVA-BN-WEV vaccine encodes the envelope surface proteins of the 3 viruses and is thereby potentially able to protect against them all, as previously demonstrated in animal models. This first-in-human study assessed the safety, tolerability, and immunogenicity of MVA-BN-WEV vaccine in healthy adult participants. METHODS: Forty-five participants were enrolled into 3 dose groups (1 × 10E7 Inf.U, 1 × 10E8 Inf.U, and 2 × 10E8 Inf.U), received 2 doses 4 weeks apart, and were then monitored for 6 months. RESULTS: The safety profile of MVA-BN-WEV was acceptable at all administered doses, with incidence of local solicited AEs increased with increasing dose and no other clinically meaningful differences between dose groups. One SAE (Grade 2 pleural effusion) was reported in the lowest dose group and assessed as possibly related. No AEs resulted in death or led to withdrawal from the second vaccination or from the trial. The most common local solicited AE was injection site pain, and general solicited AEs were headache, fatigue, and myalgia. MVA-BN-WEV induced humoral immune responses; WEEV-, EEEV- and VEEV-specific neutralizing antibody responses peaked 2 weeks following the second vaccination, and the magnitude of these responses increased with dose escalation. The highest dose resulted in seroconversion of all (100 %) participants for WEEV and VEEV and 92.9 % for EEEV, 2 weeks following second vaccination, and durability was observed for 6 months. MVA-BN-WEV induced cellular immune responses to VEEV E1 and E2 (EEEV and WEEV not tested) and a dose effect for peptide pool E2. CONCLUSION: The study demonstrated that MVA-BN-WEV is well tolerated, induces immune responses, and is suitable for further development. CLINICAL TRIAL REGISTRY NUMBER: NCT04131595.
引用
- Fierro C, Weidenthaler H, Vidojkovic S, et al. Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial. Vaccine. 2024. PMID: 38494412. doi:10.1016/j.vaccine.2024.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。